A. MENARINI INDUSTRIE
FARMACEUTICHE RIUNITE SRL
Via Sette Santi, 1
50131 - Firenze (Firenze)
Phone +39 055 56801
Fax +39 055 582771
Everyday we put our values into action. 4 values, which have given life to Menarini and shaped its history.
Menarini is investing in advanced science and technology to develop a pipeline of new products that make a difference to the lives of patients affected by serious conditions.
MENARINI is a fully integrated privately owned pharma company with a long and successful heritage in strategic partnering across the globe. We have a profound know-how stemming from our strong R&D capabilities in key therapeutic areas, coupled with our excellence in commercial execution and our powerful direct presence on a global basis.
Our corporate dedicated Business Development team is committed to assess and explore innovative new opportunities.
Donations of backpacks and cases for school, distribution of meals and medicines, promotion of sport, support for pregnant women and much more: being responsible for Menarini means transforming good intentions into concrete efforts. By helping others, we want to contribute to improve the world around us, starting with us.
Discover our stories from all over the world
What does it really make Menarini unique? The diversity and authenticity of our key resource - the People.
Our cultural diversity helps us to drive innovation, adapt to business changes, face challenges, inspire ideas and develop our growth.
Menarini employees make all the difference, every day.
Ogni giorno mettiamo in pratica i nostri valori. 4 valori, che hanno dato vita a Menarini e ne hanno forgiato la storia.
Menarini investe continuamente nella scienza e nelle tecnologie all'avanguardia per lo sviluppo di una pipeline di nuovi prodotti che facciano la differenza nella vita dei pazienti affetti da gravi patologie.
Menarini è un’azienda privata completamente integrata con una lunga storia di collaborazioni di successo in tutto il Mondo.
In Menarini abbiamo una conoscenza ed esperienza consolidata frutto della nostra capacità di Ricerca & Sviluppo nelle aree terapeutiche chiave, accompagnate da un’eccellente presenza capillare in tutto il Mondo.
Il nostro Team dedicato di Business Development è impegnato a valutare ed esplorare nuove opportunità innovative.
Dalla distribuzione di pasti e medicinali, dai kit per andare a scuola alla promozione dello sport all'aiuto per le donne in gravidanza: essere responsabili, per noi di Menarini, significa tradurre le buone intenzioni in sforzi concreti. Aiutando gli altri diamo il nostro contributo a migliorare il mondo che ci circonda, a partire da noi.
Scopri le nostre storie da tutto il mondo
Che cosa rende davvero Menarini unica? La diversità ed autenticità del nostro valore più importante - le Persone.
La nostra diversità culturale ci aiuta a guidare l'innovazione, ad adattarci ai cambiamenti di mercato, ad affrontare le sfide, ad ispirare idee e a promuovere la nostra crescita.
Chi lavora in Menarini fa la differenza, ogni giorno.
Antibiotics should be used appropriately to preserve their effectiveness and slow down the emergence of new resistance.
Antibiotics save lives. When patients require them, the benefits usually outweigh the risks from side effects and the potential for the development of resistance.
As older antibiotics lose their potency due to the rise in resistant bacteria, treatments for the safe and effective management of multi-drug resistant infections decrease.
Research and development in antibiotics is associated with high failure rates and significant costs. As a result, many pharmaceutical companies have divested from this area over the years, instead choosing to focus on therapeutic areas with higher commercial returns.
As of December 2019, only 12 antibiotics were in the late stages of development of which only a handful will reach patients. In contrast, more than 700 oncological molecules are in the late phases of development. If this trend continues, the arsenal to combat resistant bacteria will soon be depleted.
In light of this situation, Menarini has taken the decision to play a role in the fight against Antimicrobial Resistance (AMR) having recently expanded its product portfolio by adding three innovative antibiotics.
To further reinforce its commitment to providing effective and innovative solutions to treat resistant infections, Menarini has become an active partner of the AMR Action Fund, along with other leading pharmaceutical companies investing more than $1 billion. This collaboration aims to bring 2 to 4 innovative antibiotics to patients by the end of 2030, bolstering the antibiotics research and development environment with industry resources, knowledge and expertise. This unique platform in collaboration with its strategic partners, will facilitate the necessary policy reforms to encourage appropriate investment in antibiotics R&D.
“Infection in Focus” has been created by Menarini with the goal of increasing awareness of AMR and fighting life-threatening bacterial infections, a rising global threat.
“Never has the threat of antimicrobial resistance been more immediate and the need for solutions more urgent,” says Dr Tedros Adhanom Ghebreyesus, Director-General of WHO.
Antibiotic resistance presents a huge threat to the achievements of modern medicine. Organ transplantation, chemotherapy and surgery such as caesarean section, become more and more dangerous without effective antibiotics to prevent and treat infections.
Numerous initiatives are underway to reduce antimicrobial resistance, but we also need countries and the pharmaceutical industry to step up and contribute with sustainable funding and innovative new medicines.” (ref. WHO website)
Menarini is committed to developing, commercializing and providing access to new antibiotics.
Menarini is striving against resistant infections and to reduce morbidity and mortality rates.
Menarini supports the responsible use of antibiotics through global antimicrobial stewardship programmes, based on providing the right antibiotic to the right patient at the right time.
Providing relevant stakeholders significant clinical and health-economic evidence to drive treatment decisions and pathways.
The risk of antibiotics resistance is rapidly increasing.
There is a need for urgent action: everyone must play a part.
The biopharmaceutical industry has a key role to play in the fight against antibiotic resistance.
Antimicrobial resistance (AMR) represents a global public health threat.
The consequences of AMR on health, healthcare system and itseconomic burden are extraordinary.
Menarini � un�azienda privata completamente integrata con una lunga storia di collaborazioni di successo in tutto il Mondo.
In Menarini abbiamo una conoscenza ed esperienza consolidata frutto della nostra capacità di Ricerca & Sviluppo nelle aree terapeutiche chiave, accompagnate da un�eccellente presenza capillare in tutto il Mondo.
Il nostro Team dedicato di Business Development � impegnato a valutare ed esplorare nuove opportunità innovative.